ConductScience.org, home

Paper36968952

Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019-21).

Sader HS and 4 others. JAC Antimicrob Resist, 2023. Cited by 41 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019-21). Papers, record 36968952. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36968952

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019-21).
PubMed
Journal
JAC Antimicrob Resist
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
41
iCite
Relative citation ratio, by iCite
6.76
iCite
Revised in PubMed
2023-03-28
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References26

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
114,506,051Role of Klebsiella pneumoniae OmpK35 porin in antimicrobial resistance.Antimicrob Agents Chemother2003https://conductscience.org/library/papers/14506051PubMed
230,895,209The Importance of Antimicrobial Resistance Monitoring Worldwide and the Origins of SENTRY Antimicrobial Surveillance Program.Open Forum Infect Dis2019https://conductscience.org/library/papers/30895209PubMed
328,630,192In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015.Antimicrob Agents Chemother2017https://conductscience.org/library/papers/28630192PubMed
427,939,093Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission.Int J Antimicrob Agents2017https://conductscience.org/library/papers/27939093PubMed
535,372,099Global Threat of Carbapenem-Resistant Gram-Negative Bacteria.Front Cell Infect Microbiol2022https://conductscience.org/library/papers/35372099PubMed
632,387,260Genetic diversity and in vitro activity of ceftazidime/avibactam and aztreonam/avibactam against imipenem-resistant Enterobacteriaceae isolates in Southwest China: A single-centre study.J Glob Antimicrob Resist2020https://conductscience.org/library/papers/32387260PubMed
722,506,599SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing.J Comput Biol2012https://conductscience.org/library/papers/22506599PubMed
834,379,310Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review.Infect Dis Ther2021https://conductscience.org/library/papers/34379310PubMed
934,436,603Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019.J Antimicrob Chemother2021https://conductscience.org/library/papers/34436603PubMed
1032,427,286Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales.Clin Infect Dis2021https://conductscience.org/library/papers/32427286PubMed
1120,003,500BLAST+: architecture and applications.BMC Bioinformatics2009https://conductscience.org/library/papers/20003500PubMed
1235,669,117Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens.Front Cell Infect Microbiol2022https://conductscience.org/library/papers/35669117PubMed
1332,417,206
Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.
Int J Antimicrob Agents2020https://conductscience.org/library/papers/32417206PubMed
1431,828,337Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study.J Antimicrob Chemother2020https://conductscience.org/library/papers/31828337PubMed
1525,267,671
Evaluation of clonality and carbapenem resistance mechanisms among Acinetobacter baumannii-Acinetobacter calcoaceticus complex and Enterobacteriaceae isolates collected in European and Mediterranean countries and detection of two novel β-lactamases, GES-22 and VIM-35.
Antimicrob Agents Chemother2014https://conductscience.org/library/papers/25267671PubMed
1626,926,646Identification of Novel VEB β-Lactamase Enzymes and Their Impact on Avibactam Inhibition.Antimicrob Agents Chemother2016https://conductscience.org/library/papers/26926646PubMed
1732,988,825Genetic Features Leading to Reduced Susceptibility to Aztreonam-Avibactam among Metallo-β-Lactamase-Producing Escherichia coli Isolates.Antimicrob Agents Chemother2020https://conductscience.org/library/papers/32988825PubMed
1832,102,899Epidemiology of β-Lactamase-Producing Pathogens.Clin Microbiol Rev2020https://conductscience.org/library/papers/32102899PubMed
193,512,234Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.Drugs1986https://conductscience.org/library/papers/3512234PubMed
2032,855,986The Clinical and Molecular Epidemiology of Noncarbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae: A Case-Case-Control Matched Analysis.Open Forum Infect Dis2020https://conductscience.org/library/papers/32855986PubMed

See all 26 references

Cited by26

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 41 citations.

PMIDTitleJournalYearIn PapersSource
42,938,683In Vitro Activity of Eravacycline, Aztreonam-Avibactam, and Cefiderocol Against Multidrug-Resistant Gram-Negative Clinical Isolates from a Romanian Tertiary Hospital.Antibiotics (Basel)2026https://conductscience.org/library/papers/42938683PubMed
42,714,383Impact of PBP3 insertions and β-lactamase-encoding genes on the susceptibility of Escherichia coli isolates belonging to high-risk clones against aztreonam-avibactam and comparator agents.Antimicrob Agents Chemother2026https://conductscience.org/library/papers/42714383PubMed
42,379,811In vitro activity of aztreonam-avibactam and comparators against Enterobacterales isolated from bloodstream infections: ATLAS/ surveillance, 2021-2022.Microbiol Spectr2026https://conductscience.org/library/papers/42379811PubMed
41,868,017Real-World Evidence and Multidrug Resistant Infections: How Can We Leverage RWE to Improve Patient Outcome with the Novel Beta-Lactam and Beta-Lactam/Beta-Lactamase Inhibitor Combinations.Infect Drug Resist2026https://conductscience.org/library/papers/41868017PubMed
41,347,523Activity of aztreonam-avibactam, cefiderocol, and cefepime-taniborbactam against a global collection of genetically characterized metallo-β-lactamase-producing Enterobacterales.Antimicrob Agents Chemother2026https://conductscience.org/library/papers/41347523PubMed
41,258,612Aztreonam-Avibactam: A Review in the Treatment of Serious Bacterial Infections Caused by Aerobic Gram-Negative Organisms.Drugs2026https://conductscience.org/library/papers/41258612PubMed
40,981,473Molecular characterization of carbapenem-resistant Enterobacterales (CRE) and in vitro activity of novel beta lactams against CRE isolates from Malaysia.Microbiol Spectr2025https://conductscience.org/library/papers/40981473PubMed
40,727,714Aztreonam-avibactam for the treatment of serious infections caused by metallo-β-lactamase-producing Gram-negative pathogens: a Phase 3 randomized trial (ASSEMBLE).JAC Antimicrob Resist2025https://conductscience.org/library/papers/40727714PubMed
40,530,972Population pharmacokinetic/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients.Antimicrob Agents Chemother2025https://conductscience.org/library/papers/40530972PubMed
40,172,627Newly developed antibiotics against multidrug-resistant and carbapenem-resistant Gram-negative bacteria: action and resistance mechanisms.Arch Microbiol2025https://conductscience.org/library/papers/40172627PubMed
39,918,316Evaluation of two gradient diffusion tests to determine susceptibility to aztreonam and ceftazidime-avibactam in combination.Antimicrob Agents Chemother2025https://conductscience.org/library/papers/39918316PubMed
39,774,263Aztreonam-avibactam: a new combination with activity against multidrug-resistant Klebsiella pneumoniae complex.J Antibiot (Tokyo)2025https://conductscience.org/library/papers/39774263PubMed
39,766,529National Multicenter Study on the Prevalence of Carbapenemase-Producing Enterobacteriaceae in the Post-COVID-19 Era in Argentina: The RECAPT-AR Study.Antibiotics (Basel)2024https://conductscience.org/library/papers/39766529PubMed
39,384,682In vivo development of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae infections: a case series.Eur J Clin Microbiol Infect Dis2024https://conductscience.org/library/papers/39384682PubMed
39,352,652Navigating the Current Treatment Landscape of Metallo-β-Lactamase-Producing Gram-Negative Infections: What are the Limitations?Infect Dis Ther2024https://conductscience.org/library/papers/39352652PubMed
39,292,563Gut microbiota-derived butyrate selectively interferes with growth of carbapenem-resistant Escherichia coli based on their resistance mechanism.Gut Microbes2024https://conductscience.org/library/papers/39292563PubMed
39,200,065Practical Application of Aztreonam-Avibactam as a Treatment Strategy for Ambler Class B Metallo-β-Lactamase Producing Enterobacteriaceae.Antibiotics (Basel)2024https://conductscience.org/library/papers/39200065PubMed
38,800,756Friends or foes? Novel antimicrobials tackling MDR/XDR Gram-negative bacteria: a systematic review.Front Microbiol2024https://conductscience.org/library/papers/38800756PubMed
38,399,502Carbapenem-Resistant Enterobacteriaceae in Urinary Tract Infections: From Biological Insights to Emerging Therapeutic Alternatives.Medicina (Kaunas)2024https://conductscience.org/library/papers/38399502PubMed
38,252,170Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation.Eur J Clin Pharmacol2024https://conductscience.org/library/papers/38252170PubMed

See all 26 cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
MBL3P50,639PubTator's text mininghttps://conductscience.org/library/genes/50639

Source NCBI Gene

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36968952

GET https://conductscience.org/api/papers/v1/36968952/references?page=2